US FDA Issues Warning on Popular Diabetes Drugs Over Vision Loss Risk

The US Food and Drug Administration has issued a safety warning regarding a group of popular diabetes and weight loss medications, citing a potential risk of sudden vision loss in patients. The alert covers drugs containing semaglutide and tirzepatide, including Ozempic and Wegovy used for diabetes management and weight loss, as well as Mounjaro prescribed for blood sugar control.

The condition in question is non-arteritic anterior ischemic optic neuropathy, or NAION, a rare disorder that occurs when blood flow to the optic nerve becomes severely restricted. This reduction in blood supply to the nerve that transmits visual information from the eye to the brain can result in the sudden, painless loss of vision in one eye. The condition can develop without warning and may be permanent.

The FDA's warning comes as these medications have gained significant popularity in recent years, both for their intended use in managing type 2 diabetes and increasingly for weight management. Healthcare providers and patients using these drugs have been urged to remain alert to any symptoms of sudden vision changes and to seek immediate medical attention if such symptoms occur.

While the FDA has not mandated withdrawal of these medications, the agency has recommended that healthcare professionals discuss the potential risks with patients before prescribing these drugs. Patients currently taking these medications have been advised to consult their physicians before making any changes to their treatment regimen and to report any vision-related concerns promptly.